Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arjo ABFRA:A39 +0.58%74 3-Year ROIIC % is -0.13 as of Dec. 2025. GuruFocus rates FRA:A39 with a GF Score™ of 74/100 and a GF Value™ of €3.13 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 112 Medical Distribution companies, Arjo AB ranks worse than 57.14% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Arjo AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -0.13%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Arjo AB's 3-Year ROIIC % or its related term are showing as below:
FRA:A39's 3-Year ROIIC % is ranked worse than 57.14% of 112
companies
in the Medical Distribution industry
Industry Median: 2.295
vs FRA:A39: -0.13
Arjo AB (FRA:A39) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Arjo AB 3-Year ROIIC % Related Terms
Arjo AB 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Arjo AB's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:A39 vs MCK, CAH, COR: 3-Year ROIIC % Comparison
For the Medical Distribution subindustry, Arjo AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arjo AB 3-Year ROIIC % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arjo AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Arjo AB's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Arjo AB (FRA:A39) has a 3-Year ROIIC % of -0.13 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Arjo AB and its competitors. According to the industry distribution chart, Arjo AB ranks #64 out of 112 companies in the Medical Distribution industry, placing it in the top 57.1%.
Is Arjo AB's 3-Year ROIIC % too high?
Arjo AB's current 3-Year ROIIC % is -0.13. Based on the distribution chart, Arjo AB ranks #64 out of 112 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, Arjo AB has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Arjo AB's 3-Year ROIIC % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Arjo AB ranks #64 out of 112 companies for 3-Year ROIIC %. This places Arjo AB in the lower half of its industry. The industry median 3-Year ROIIC % is 2.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Distribution company?
The median 3-Year ROIIC % among Medical Distribution companies is 2.30, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Arjo AB and its competitors. For the Medical Distribution industry, the median 3-Year ROIIC % is 2.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arjo AB's current 3-Year ROIIC % is -0.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arjo AB stock overvalued right now?
Based on GuruFocus' analysis, Arjo AB (FRA:A39) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.13, compared to a current price of €2.44 — trading 22.1% below its estimated fair value. The current 3-Year ROIIC % is -0.13. Arjo AB's overall GF Score™ is 74/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Arjo AB (FRA:A39), the current 3-Year ROIIC % is -0.13 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arjo AB (FRA:A39) Overvalued in 2026?
Based on GuruFocus' analysis, Arjo AB stock appears to be undervalued.
The current stock price of €2.44 is trading 22.1% below its estimated GF Value™ of €3.13.
GuruFocus considers Arjo AB to be Modestly Undervalued.
Key valuation signals for FRA:A39:
3-Year ROIIC %: -0.13
GF Value™: €3.13 vs. price of €2.44 (22.1% below fair value)
No single metric tells the full story. See the FRA:A39 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arjo AB is a supplier of medical devices, services, and solutions in Sweden. It serves its services to private and public institutions with acute care and long-term care. The company's offering includes products and solutions for patient handling, hygiene, disinfection, medical beds, therapeutic surfaces, venous thromboembolism (VTE) prevention and diagnostics. The company includes segments: Global Sales, North America, Diagnostics.
74GF Score
Get the complete analysis for FRA:A39
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A39 has been successfully added to your 
